FRAZIER LIFE SCIENCES MANAGEMENT L P
Q2 2022 Form 13-F
PALO ALTO, CALIFORNIA
CIK 0001892134
· CRD 317522
· SEC-registered investment adviser
$1.1B Reported Value Total
FRAZIER LIFE SCIENCES MANAGEMENT, LP reports 7 total accounts under management (AUM). There are 7 discretionary accounts valued at $4,035,931,342, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
9 funds
· $7.3B gross asset value
Venture Capital Fund: $3.3B · Hedge Fund: $3.2B · Private Equity Fund: $783.7M
Source: Form ADV filed 2026-03-31
Reported value
$1.1B
Quarter over quarter
-7.3%
Holdings
41
Top-10 concentration
68.2%
Key People
Form ADV owners & control persons
Patrick James Heron
MEMBER
James Newman Topper
MEMBER
James Brush
GENERAL PARTNER & PORTFOLIO MANAGER
Filing Navigation
13F Metrics
Loading 13F Metrics
Q2 2022 13F record
Q2 2022 13F filing summary
| Period of report | June 30, 2022 |
|---|---|
| Filed | August 10, 2022 |
| Form | 13F-HR |
| Reported value | $1.1B |
| Positions | 41 |
| Change in reported value | -9.7% |
| New positions | 2 |
| Exited positions | 3 |
| Position turnover | 11.4% |
| Top-10 concentration | 68.2% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q2 2026 13F
Filed Aug 14, 2026
|
41 | $4.6B |
|
Q1 2026 13F
Filed May 15, 2026
|
38 | $3.9B |
|
Q4 2025 13F
Filed Feb 13, 2026
|
40 | $3.7B |
|
Q3 2025 13F
Filed Nov 14, 2025
|
47 | $3.3B |
|
Q2 2025 13F
Filed Aug 14, 2025
|
49 | $2.5B |
|
Q1 2025 13F
Filed May 15, 2025
|
47 | $2.2B |
|
Q4 2024 13F
Filed Feb 18, 2025
|
50 | $2.4B |
|
Q3 2024 13F
Filed Nov 15, 2024
|
53 | $2.5B |
|
Q2 2024 13F
Filed Aug 15, 2024
|
49 | $2.1B |
|
Q1 2024 13F
Filed May 15, 2024
|
50 | $2.4B |
|
Q4 2023 13F
Filed Feb 14, 2024
|
49 | $1.9B |
|
Q3 2023 13F
Filed Nov 14, 2023
|
51 | $1.5B |
|
Q2 2023 13F
Filed Aug 14, 2023
|
48 | $1.7B |
|
Q1 2023 13F
Filed May 15, 2023
|
49 | $1.4B |
|
Q4 2022 13F
Filed Feb 3, 2023
|
44 | $1.6B |
|
Q3 2022 13F
Filed Nov 14, 2022
|
43 | $1.3B |
|
Q2 2022 13F
Filed Aug 10, 2022
|
41 | $1.1B |
|
Q1 2022 13F
Filed May 16, 2022
|
42 | $1.2B |
Top 20 holdings · Q2 2022
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | ARQT ARCUTIS BIOTHERAPEUTICS INC | $179.7M | 16.96% |
| 2 | HLVX HILLEVAX INC | $101.5M | 9.58% |
| 3 | KRYS KRYSTAL BIOTECH INC | $71.9M | 6.79% |
| 4 | MIRM MIRUM PHARMACEUTICALS INC | $69.4M | 6.55% |
| 5 | KDNY CHINOOK THERAPEUTICS INC | $62.9M | 5.93% |
| 6 | SNDX SYNDAX PHARMACEUTICALS INC | $61.5M | 5.8% |
| 7 | PHAT PHATHOM PHARMACEUTICALS INC | $49.2M | 4.64% |
| 8 | SRRA SIERRA ONCOLOGY INC | $47.9M | 4.52% |
| 9 | IMGO IMAGO BIOSCIENCES INC | $39.8M | 3.75% |
| 10 | PCVX VAXCYTE INC | $38.9M | 3.67% |
| 11 | CRNX CRINETICS PHARMACEUTICALS IN | $26.4M | 2.49% |
| 12 | TARS TARSUS PHARMACEUTICALS INC | $26.1M | 2.46% |
| 13 | ALPN ALPINE IMMUNE SCIENCES INC | $25.4M | 2.4% |
| 14 | TCDAQ TRICIDA INC | $20.2M | 1.9% |
| 15 | COGT COGENT BIOSCIENCES INC | $18.9M | 1.78% |
| 16 | ANAB ANAPTYSBIO INC | $18.3M | 1.72% |
| 17 | GRCL GRACELL BIOTECHNOLOGIES INC | $17.1M | 1.62% |
| 18 | KALV KALVISTA PHARMACEUTICALS INC | $15.5M | 1.46% |
| 19 | MRUS MERUS N V | $15.3M | 1.44% |
| 20 | FLACU FRAZIER LIFESCIENCES ACQU CO | $14.8M | 1.4% |
Values as reported on the Q2 2022 Form 13F. Every position is in the holdings table below.